Abstract
The oncolytic viruses now hold a promise of new therapeutic strategy for cancer. Its concept has inspired a wave of commercial research and development activities for the products of this category in China since 1998. The first commercialized oncolytic virus product in the world, Oncorine (H101), developed by Shanghai Sunway Biotech Co., Ltd since 1999, was approved by Chinese SFDA in November, 2005 for nasopharyngeal carcinoma in combination with chemotherapy after the phase III clinical trial, and finally acquired GMP certificate in August, 2006. This review introduces how Oncorine was successfully developed in China, and how the Chinese market responded after it was launched into the market in 2006.
Keywords: Oncorine, oncolytic virus, nasopharyngeal carcinoma, cancer, chemotherapy, virotherapy.
Current Cancer Drug Targets
Title:Oncorine, the World First Oncolytic Virus Medicine and its Update in China
Volume: 18 Issue: 2
Author(s): Min Liang*
Affiliation:
- Totbiopharm Shanghai R&D Center, 781 Cailun Road, Shanghai, 201203,China
Keywords: Oncorine, oncolytic virus, nasopharyngeal carcinoma, cancer, chemotherapy, virotherapy.
Abstract: The oncolytic viruses now hold a promise of new therapeutic strategy for cancer. Its concept has inspired a wave of commercial research and development activities for the products of this category in China since 1998. The first commercialized oncolytic virus product in the world, Oncorine (H101), developed by Shanghai Sunway Biotech Co., Ltd since 1999, was approved by Chinese SFDA in November, 2005 for nasopharyngeal carcinoma in combination with chemotherapy after the phase III clinical trial, and finally acquired GMP certificate in August, 2006. This review introduces how Oncorine was successfully developed in China, and how the Chinese market responded after it was launched into the market in 2006.
Export Options
About this article
Cite this article as:
Liang Min *, Oncorine, the World First Oncolytic Virus Medicine and its Update in China, Current Cancer Drug Targets 2018; 18 (2) . https://dx.doi.org/10.2174/1568009618666171129221503
DOI https://dx.doi.org/10.2174/1568009618666171129221503 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy Gabapentin and Pregabalin for the Acute Post-operative Pain Management. A Systematic-narrative Review of the Recent Clinical Evidences
Current Drug Targets Lanthanides as Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry System Models, Assays and Endpoint Parameters to Evaluate Anticancer Compounds During Preclinical Screening
Current Medicinal Chemistry Effects of Epirubicin and Cisplatin Against 4T1 Breast Cancer Cells are Enhanced by Myrtucommulone-A
Anti-Cancer Agents in Medicinal Chemistry Editorial: The Role of Stereotactic Body Radiotherapy: A Review
Current Cancer Therapy Reviews Application of Nano- and Micro-Particles on the Topical Therapy of Skin-Related Immune Disorders
Current Pharmaceutical Design Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology Simultaneous Quantification of Paclitaxel Prodrug and its Released Paclitaxel in Human Plasma by UPLC-MS/MS
Current Pharmaceutical Analysis The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF
Current Angiogenesis (Discontinued) Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response
Current Medicinal Chemistry Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry Identification of Novel Small-Molecule ASGP-R Ligands
Current Drug Delivery Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Designing Prodrugs Based on Special Residues of Human Serum Albumin
Current Topics in Medicinal Chemistry Autoantibody Profiles as Biomarkers for Response to Therapy and Early Detection of Cancer
Current Cancer Therapy Reviews AKT Signaling in Regulating Angiogenesis
Current Cancer Drug Targets New Ketonethiosemicarbazones for Melanogenesis Inhibition
Current Bioactive Compounds